| __timestamp | Neurocrine Biosciences, Inc. | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 46425000 | 11768000 |
| Thursday, January 1, 2015 | 81491000 | 15152000 |
| Friday, January 1, 2016 | 94291000 | 19828000 |
| Sunday, January 1, 2017 | 121827000 | 25573000 |
| Monday, January 1, 2018 | 160524000 | 23634000 |
| Tuesday, January 1, 2019 | 200000000 | 38845000 |
| Wednesday, January 1, 2020 | 275000000 | 50523000 |
| Friday, January 1, 2021 | 328100000 | 75463000 |
| Saturday, January 1, 2022 | 463800000 | 105767000 |
| Sunday, January 1, 2023 | 565000000 | 167512000 |
| Monday, January 1, 2024 | 731100000 |
Unleashing the power of data
In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Neurocrine Biosciences increased its R&D spending by over 1,100%, reaching a peak in 2023. In contrast, Xenon Pharmaceuticals, while also increasing its R&D budget, saw a more modest growth of approximately 1,300% over the same period.
This trend highlights Neurocrine's aggressive push towards innovation, with its R&D expenses consistently outpacing those of Xenon. By 2023, Neurocrine's R&D spending was more than three times that of Xenon, underscoring its strategic focus on pioneering new treatments. As the biotech landscape continues to evolve, these investments may well dictate the future leaders in the industry.
Analyzing R&D Budgets: Bristol-Myers Squibb Company vs Xenon Pharmaceuticals Inc.
Comparing Innovation Spending: Neurocrine Biosciences, Inc. and Alkermes plc
R&D Spending Showdown: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
R&D Insights: How Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG Allocate Funds
R&D Spending Showdown: Neurocrine Biosciences, Inc. vs Vericel Corporation
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Neurocrine Biosciences, Inc. vs Dynavax Technologies Corporation: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Ionis Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.
Research and Development: Comparing Key Metrics for Amneal Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. or Arrowhead Pharmaceuticals, Inc.: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for Xenon Pharmaceuticals Inc. and Soleno Therapeutics, Inc.
Analyzing R&D Budgets: Xenon Pharmaceuticals Inc. vs Amphastar Pharmaceuticals, Inc.